Breast Cancer Prognosis

August 20, 2015

Contents

1 Datasets

From MetaGxBreast, we selected patients from studies which tracked recurence-free survival. When recurrence-free survival was unavailable, we used distant metastatis-free survival. We identified 2749 patients from 16 datasets.

	Number of samples
CAL	117
DFHCC	115
EMC2	204
MAINZ	200
MSK	82
NCI	99
NKI	319
PNC	85
STK	159
STNO2	95
TRANSBIG	198
UCSF	133
UNC4	240
UNT	125
UPP	234
VDX	344
Sum	2749

2 Summary of Results

Gene Name	P-value	Hazard Ratio
ESR1	0.00237	0.75 [0.62, 0.90]
ERBB2	0.41959	1.09 [0.89, 1.33]
STAT1	0.26143	1.12 [0.92, 1.35]
CASP3	0.13474	1.14 [0.96, 1.34]
PLAU	0.02989	1.17 [1.02, 1.36]
VEGF	0.00500	1.29 [1.08, 1.54]
AURKA	0.00000	1.64 [1.33, 2.02]




ESR1
0.75 [0.62 , 0.90]
ERBB2
1.09 [0.89 , 1.33]
STAT1
1.12 [0.92 , 1.35]
CASP3
1.14 [0.96 , 1.34]
PLAU
1.17 [1.02 , 1.36]
VEGF
1.29 [1.08 , 1.54]
AURKA
1.64 [1.33 , 2.02]
0.25
0.50
1.00
2.00
4.00
Hazard Ratio

3 ESR1





Random effects model: 0.75 [0.62, 0.90], p = 2.4E-03

4 ERBB2





Random effects model: 1.09 [0.89, 1.33], p = 4.2E-01

5 STAT1





Random effects model: 1.12 [0.92, 1.35], p = 2.6E-01

6 CASP3





Random effects model: 1.14 [0.96, 1.34], p = 1.3E-01

7 PLAU





Random effects model: 1.17 [1.02, 1.36], p = 3.0E-02

8 VEGF





Random effects model: 1.29 [1.08, 1.54], p = 5.0E-03

9 AURKA





Random effects model: 1.64 [1.33, 2.02], p = 4.4E-06